Plasma Protein Biomarkers for Depression and Schizophrenia by Multi Analyte Profiling of Case-Control Collections

被引:284
作者
Domenici, Enrico [1 ]
Wille, David R. [2 ]
Tozzi, Federica [3 ]
Prokopenko, Inga [4 ]
Miller, Sam [2 ]
McKeown, Astrid [5 ]
Brittain, Claire [2 ]
Rujescu, Dan [6 ]
Giegling, Ina [6 ]
Turck, Christoph W. [7 ]
Holsboer, Florian [7 ]
Bullmore, Edward T. [5 ,8 ]
Middleton, Lefkos [9 ]
Merlo-Pich, Emilio [1 ]
Alexander, Robert C. [1 ]
Muglia, Pierandrea [1 ]
机构
[1] GlaxoSmithKline R&D, Neurosci Ctr Excellence Drug Discovery, Verona, Italy
[2] GlaxoSmithKline R&D, Discovery Stat Europe, Harlow, Essex, England
[3] GlaxoSmithKline R&D, Quantitat Sci, Verona, Italy
[4] GlaxoSmithKline R&D, Div Genet, Drug Discovery, Verona, Italy
[5] Addenbrookes Hosp, GSK Clin Units, Cambridge, England
[6] Univ Munich, Dept Psychiat & Psychotherapy, Munich, Germany
[7] Max Planck Inst Psychiat, D-80804 Munich, Germany
[8] Univ Cambridge, Behav & Clin Neurosci Inst, Cambridge, England
[9] GlaxoSmithKline R&D, Div Genet, Drug Discovery, Greenford, Middx, England
来源
PLOS ONE | 2010年 / 5卷 / 02期
关键词
NECROSIS-FACTOR-ALPHA; EPIDERMAL-GROWTH-FACTOR; LONG-TERM POTENTIATION; MAJOR DEPRESSION; NEUROTROPHIC FACTOR; INSULIN-RESISTANCE; TREATMENT RESPONSE; MATRIX METALLOPROTEINASES; RECEPTOR ANTAGONIST; SERUM-LEVELS;
D O I
10.1371/journal.pone.0009166
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Despite significant research efforts aimed at understanding the neurobiological underpinnings of psychiatric disorders, the diagnosis and the evaluation of treatment of these disorders are still based solely on relatively subjective assessment of symptoms. Therefore, biological markers which could improve the current classification of psychiatry disorders, and in perspective stratify patients on a biological basis into more homogeneous clinically distinct subgroups, are highly needed. In order to identify novel candidate biological markers for major depression and schizophrenia, we have applied a focused proteomic approach using plasma samples from a large case-control collection. Patients were diagnosed according to DSM criteria using structured interviews and a number of additional clinical variables and demographic information were assessed. Plasma samples from 245 depressed patients, 229 schizophrenic patients and 254 controls were submitted to multi analyte profiling allowing the evaluation of up to 79 proteins, including a series of cytokines, chemokines and neurotrophins previously suggested to be involved in the pathophysiology of depression and schizophrenia. Univariate data analysis showed more significant p-values than would be expected by chance and highlighted several proteins belonging to pathways or mechanisms previously suspected to be involved in the pathophysiology of major depression or schizophrenia, such as insulin and MMP-9 for depression, and BDNF, EGF and a number of chemokines for schizophrenia. Multivariate analysis was carried out to improve the differentiation of cases from controls and identify the most informative panel of markers. The results illustrate the potential of plasma biomarker profiling for psychiatric disorders, when conducted in large collections. The study highlighted a set of analytes as candidate biomarker signatures for depression and schizophrenia, warranting further investigation in independent collections.
引用
收藏
页数:12
相关论文
共 55 条
  • [1] Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: Clinical implications
    Alesci, S
    Martinez, PE
    Kelkar, S
    Ilias, I
    Ronsaville, DS
    Listwak, SJ
    Ayala, AR
    Licinio, J
    Gold, HK
    Kling, MA
    Chrousos, GP
    Gold, PW
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (05) : 2522 - 2530
  • [2] In vivo roles for matrix metalloproteinase-9 in mature hippocampal synaptic physiology and plasticity
    Bozdagi, Ozlem
    Nagy, Vanja
    Kwei, Kimberly T.
    Huntley, George W.
    [J]. JOURNAL OF NEUROPHYSIOLOGY, 2007, 98 (01) : 334 - 344
  • [3] Random forests
    Breiman, L
    [J]. MACHINE LEARNING, 2001, 45 (01) : 5 - 32
  • [4] Abnormalities in serum chemokine levels in euthymic patients with Bipolar Disorder
    Brietzke, Elisa
    Kauer-Sant'Anna, Marcia
    Teixeira, Antonio Lucio
    Kapczinski, Flavio
    [J]. BRAIN BEHAVIOR AND IMMUNITY, 2009, 23 (08) : 1079 - 1082
  • [5] Involvement of tissue inhibition of metalloproteinases-1 in learning and memory in mice
    Chaillan, F. A.
    Rivera, S.
    Marchetti, E.
    Jourquin, J.
    Werb, Z.
    Soloway, P. D.
    Khrestchatisky, M.
    Roman, F. S.
    [J]. BEHAVIOURAL BRAIN RESEARCH, 2006, 173 (02) : 191 - 198
  • [6] Validation and comparison of two multiplex technologies, Luminex® and Mesoscale Discovery, for human cytokine profiling
    Chowdhury, Ferdousi
    Williams, Anthony
    Johnson, Peter
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 2009, 340 (01) : 55 - 64
  • [7] CONNOR TJ, 2004, HDB EXPT PHARM ANTID, V157, P117
  • [8] Domenici Enrico, 2007, Expert Opin Med Diagn, V1, P235, DOI 10.1517/17530059.1.2.235
  • [9] Depression: An Important Comorbidity With Metabolic Syndrome in a General Population
    Dunbar, James A.
    Reddy, Prasuna
    Davis-Lameloise, Nathalie
    Philpot, Benjamin
    Laatikainen, Tiina
    Kilkkinen, Annamari
    Bunker, Stephen J.
    Best, James D.
    Vartiainen, Erkki
    Lo, Sing Kai
    Janus, Edward D.
    [J]. DIABETES CARE, 2008, 31 (12) : 2368 - 2373
  • [10] Cytokines as mediators of depression: What can we learn from animal studies?
    Dunn, AJ
    Swiergiel, AH
    de Beaurepaire, R
    [J]. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2005, 29 (4-5) : 891 - 909